Follow us...

 

Search News Archives

Monthly Newsletter

 

Lab Bulletin May Newsletter

view the latest issue

Subscribe

News Channels

 

New Laboratory Products

 

Lab News

 

Microscopy & Image Analysis

 

Separation Science

 

Research & Case Studies

 

Literature

 

Videos

 

Events | Webinars

 

 

 

Conferences | Events
3P Biopharmaceuticals

3P Biopharmaceuticals

3P Biopharmaceuticals

Products

Contact 3P Biopharmaceuticals


If you have not logged into the website then please enter your details below.

All articles from 3P Biopharmaceuticals

  3P Biopharmaceuticals will participate in a major European Project aiming to develop a universal influenza virus vaccine.

3P Biopharmaceuticals will participate in the European research project FLUTCORE, financed by the European Union 7th Framework Programme (FP7). The consortium is comprised of several prestigious companies and research centers specialized in influenza virus research.

3P BiopharmaceuticalsThe European consortium will be led by iQur Ltd., which is a biotech company based in London, whose research into the tandem core™ vaccine platform forms the basis of the science behind the project. Their vaccine platform has been shown to generate powerful immune responses to several pathogens and this consortium will optimize their influenza candidate vaccine for use in the clinical setting.

 

 

Promotions

 

Media Partners